RxDoctor Payments Data

Mitchell Mock

Family Medicine · Burgettstown, PANPI 1346694585

Payments from drug & device makers

$2,059in general payments, 2019–2025

Across 70 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$369
  • Inari Medical, Inc.$353
  • Lilly USA, LLC$330
  • AstraZeneca$330
  • Medtronic$164
  • Hologic Sales And Service, LLC$150
  • plus $363 from 10 others

What the payments were for

  • Speaking & faculty fees$221%
  • Food & beverage$2,02598%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,059 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,240
Medicare patients
128
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide62$66,295
JardianceEmpagliflozin51$48,181
EliquisApixaban49$45,960
OzempicSemaglutide42$45,476
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$21,344
FarxigaDapagliflozin Propanediol16$19,785
XareltoRivaroxaban28$15,428
JanuviaSitagliptin Phosphate15$10,529
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med77$2,581
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$1,965
Gabapentin136$1,108
Cefadroxil20$1,101
Atorvastatin Calcium116$958
Omeprazole102$941
Levothyroxine Sodium126$887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$330$66,29562 claims
Boehringer IngelheimJardiance$23$48,18151 claims
PfizerEliquis$17$45,96049 claims
Novo NordiskOzempic$139$45,47642 claims
AstraZenecaBreztri Aerosphere, Farxiga$330$41,12951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Burgettstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →